Top member reports
Company Report
Last edited 3 years ago
PerformanceCommunity EngagementCommunity Endorsement
Performance (64m)
1.3% pa
Followed by
142
Straws
Sort by:
Recent
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#Clinical trial
stale
Added 3 years ago

Follow the link below to ANZCTR for full details.

Here is the main trial summary:

This study will assess the safety and effectiveness of an investigational agent (MSH2TR) used to detect lymph node spread of cancer in patients with a specific type of breast cancer, HER2-positive breast cancer.

Who is it for?
You may be eligible for this study if you are a female aged 18 or older, you have histologically confirmed HER2-positive primary breast cancer which you haven't had any prior treatment for (including surgery, radiotherapy, or systemic treatment) and you are scheduled for surgical intervention with lymph node detection by a specific diagnostic agent injection procedure being part of the surgical plan, or scheduled for a core biopsy of a lymph node that is clinically suspicious.

Study details
All enrolled participants will receive a subareolar (the pigmented area around the nipple) injection of the investigational agent after a baseline magnetic resonance imaging (MRI) scan on Day 1. The scan will last approximately 45 minutes. Participants will return for another MRI in 24 hours (Day 2) and on Day 4 to detect the lymph node spread. Also on Day 4, participants will have a tissue sample (biopsy) taken from a cancerous lymph nodes for further examination. The biopsy will be investigated for standard of care as well as a new imaging technique called magnetic relaxometry (MRX). As this study is investigating the safety of the investigational agent, participants will be asked to attend a series of seven (7) clinic visits where they will provide up to three (3) blood and urine samples.

It is hoped this research will demonstrate that a single dose of MSH2TR is safe and well tolerated. It is also hoped that MSH2TR is an effective method for detecting HER-2 positive breast cancer that has spread to lymph nodes using MRI and MRX.

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380834&isReview=true

#ASX Announcements
stale
Added 4 years ago

Imagion announced the publication of a study looking at the use of it's nanoparticles as part of a novel HIV therapy.

See the announcement for a link to the publication. It's very difficult to understand - I'm a vet and even I could hardly undertand the title, let alone the rest of the paper!

But again, great to see the potential for further new revenue streams to help fund the R&D of Imagion's core technology.

#ASX Announcements
stale
Added 4 years ago

IBX announced today that they have entered into a calloaboration agreement with Siemens to further explore the use of Imagion's MagSense nanoparticles as an MRI contrast agent.

Very exciting news and great to have attracted the interest of a huge healthcare company.

Another revenue stream opportunity to help fund the R&D and regulatory hurdles for Imagion's own imaging technology.